🧪 🧠 MS Trial Expansion, Dual Migraine-Depression Therapy, Schizophrenia Advances, Myasthenia Approval & More!
In this week’s Neuroscience Updates, we spotlight pivotal breakthroughs advancing neurology and neurodegenerative disease research.
✨ Key updates include:
✅ FDA approval of Atzumi — the first and only nasal DHE powder for acute migraine relief
🧪 Fremanezumab demonstrates dual efficacy in both migraine and depression
📈 TG Therapeutics boosts its 2025 revenue outlook after a 137% YoY surge for BRIUMVI
🧠 Immunic pivots toward disability progression after missing brain volume endpoint
🚀 ATH434 earns FDA Fast Track for Multiple System Atrophy
🔬 Anavex completes enrollment in its Phase 2 schizophrenia study
🧩 Neurocrine progresses its M4 agonist into Phase 3 for schizophrenia
⚠️ AstraZeneca exits neuroscience to refocus on high-growth therapy areas
🏥 Johnson & Johnson’s IMAAVY gets FDA approval for myasthenia gravis
💉 TRD205 begins Phase II as a non-opioid chronic pain therapy
Whether you’re in R&D, clinical development, or biotech strategy—this roundup delivers the insights you need to stay informed in a rapidly evolving field.
📢 Stay Ahead in Neuroscience Research!
✅ Like, share, and subscribe for weekly updates on neuroscience, neurodegeneration, and clinical trials
#NeuroscienceNews #BrainHealth #MultipleSclerosis #Schizophrenia #MigraineTreatment #MyastheniaGravis #FDAApproval #NeurodegenerativeDisease #ClinicalTrials #MedicalInnovation #NonOpioidPain #BiotechNews #LucidQuest #HealthcareStrategy